| Earnings (loss) per share |
| 13. | Earnings (loss) per share |
| Schedule of earnings (loss) per share | |
| | | |
| | | |
| | | |
| | |
| | |
Three months ended
May 31, | | |
Nine months ended
May 31, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Net earnings (loss) attributable to shareholders | |
$ | 2,839 | | |
$ | (218 | ) | |
$ | (21,705 | ) | |
$ | (1,758 | ) |
| Weighted average number of common shares for basic EPS(1) | |
| 331,192,969 | | |
| 293,920,641 | | |
| 311,885,537 | | |
| 293,040,937 | |
| Effect of dilutive stock options and restricted share units (“RSU”) | |
| 10,920,041 | | |
| - | | |
| - | | |
| - | |
| Weighted average number of common shares for diluted EPS(1) | |
| 342,113,011 | | |
| 293,920,641 | | |
| 311,885,537 | | |
| 293,040,937 | |
| (1) | The weighted average number of common
shares for basic and diluted EPS include 2.7 million of vested, but unissued, gross common shares relating to share-based compensation. |
For the nine months ended May 31, 2026 and corresponding periods ended
May 31, 2025, all outstanding options to purchase shares of common stock and restricted share units were excluded from the respective
computations of diluted loss per share, as the Company was in a net loss position, and all potentially dilutive instruments were anti-dilutive
and therefore not included in the calculation of diluted net loss per share.
|